high mobility group box 1 pseudogene 42Genealiases: []
Q-omics provides the consensus-scored HMGB1P42 profile across patient tissues and cancer cell-line models. HMGB1P42 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, HMGB1P42 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, HMGB1P42 RNA expression shows 6,000 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, BRCA, and STAD as cancer lineages where HMGB1P42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P42 survival associations across molecular data types. HMGB1P42 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P42 RNA expression–survival associations across cancer types. High HMGB1P42 expression shows unfavorable associations in LUSC, COAD, SKCM, THYM, ACC and BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for HMGB1P42 RNA expression.
This table summarizes HMGB1P42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P42 shows higher tumor expression in BRCA, LIHC and KIRC. The BRCA box plot shows higher HMGB1P42 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .007).
This table shows molecular features associated with HMGB1P42 in patient tissues and cancer cell lines. In patient samples, HMGB1P42 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
